Abstract
Neuroinflammation is traditionally defined as the brain's innate immune response and is also considered to be a glial-cell propagated inflammation. Increasing evidence indicates that neuroinflammation plays an important role in some cases of major depression and also that antidepressants possess anti-neuroinflammatory properties. Inhibition of neuroinflammation may represent a novel mechanism of action of antidepressant treatment. In vivo studies with animal models of neurological conditions have shown that various types of antidepressants exert inhibitory effects on the expression of inflammatory mediators, including cytokines, as well as on both microgliosis and astrogliosis in the inflamed CNS. In vitro studies using pathologically activated rodent microglia or mixed glial cells have demonstrated that various types of antidepressants diminish glial generation of inflammatory molecules. One of the most plausible mechanisms of such anti-neuroinflammatory efficacy of the drugs, as well as their antidepressant actions, seems to involve elevated intracellular cAMP levels. But the exact mechanism has still to be elucidated.
Keywords: Anti-neuroinflammatory effect, astrocytes, cytokine, major depression, microglia, Neuroinflammation, glial-cell, antidepressants, Inhibition, microgliosis, astrogliosis, CNS
Mini-Reviews in Medicinal Chemistry
Title: Antidepressants and Neuroinflammation: Can Antidepressants Calm Glial Rage Down?
Volume: 11 Issue: 7
Author(s): S. Hashioka
Affiliation:
Keywords: Anti-neuroinflammatory effect, astrocytes, cytokine, major depression, microglia, Neuroinflammation, glial-cell, antidepressants, Inhibition, microgliosis, astrogliosis, CNS
Abstract: Neuroinflammation is traditionally defined as the brain's innate immune response and is also considered to be a glial-cell propagated inflammation. Increasing evidence indicates that neuroinflammation plays an important role in some cases of major depression and also that antidepressants possess anti-neuroinflammatory properties. Inhibition of neuroinflammation may represent a novel mechanism of action of antidepressant treatment. In vivo studies with animal models of neurological conditions have shown that various types of antidepressants exert inhibitory effects on the expression of inflammatory mediators, including cytokines, as well as on both microgliosis and astrogliosis in the inflamed CNS. In vitro studies using pathologically activated rodent microglia or mixed glial cells have demonstrated that various types of antidepressants diminish glial generation of inflammatory molecules. One of the most plausible mechanisms of such anti-neuroinflammatory efficacy of the drugs, as well as their antidepressant actions, seems to involve elevated intracellular cAMP levels. But the exact mechanism has still to be elucidated.
Export Options
About this article
Cite this article as:
Hashioka S., Antidepressants and Neuroinflammation: Can Antidepressants Calm Glial Rage Down?, Mini-Reviews in Medicinal Chemistry 2011; 11 (7) . https://dx.doi.org/10.2174/138955711795906888
DOI https://dx.doi.org/10.2174/138955711795906888 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Regulatory T Cells: Major Players in the Tumor Microenvironment
Current Pharmaceutical Design IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Immune Response to Herpes Simplex Virus and γ134.5 Deleted HSV Vectors
Current Gene Therapy APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Patient-Specific Alpha-Particle Dosimetry
Current Radiopharmaceuticals Muscarinic Acetylcholine Receptors: New Potential Therapeutic Targets in Antinociception and in Cancer Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Progress in Research of K<sub>V</sub>1.1 and K<sub>V</sub>1.3 Channels as Therapeutic Targets
Current Topics in Medicinal Chemistry Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Neuroprotection & Mechanism of Ethanol in Stroke and Traumatic Brain Injury Therapy: New Prospects for an Ancient Drug
Current Drug Targets <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Current Pharmaceutical Design An Update of the Classical and Novel Methods Used for Measuring Fast Neurotransmitters During Normal and Brain Altered Function
Current Neuropharmacology Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Proteomic Analysis of Mitochondrial Proteins on the Mechanism of Apoptotic Under Amorphophallus konjac Tuber (KONJAC) Extracts in Gas tric Cancer Cell
Current Proteomics Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Oligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer Therapy
Current Pharmaceutical Design Peptide Phage Display: Opportunities for Development of Personalized Anti-Cancer Strategies
Anti-Cancer Agents in Medicinal Chemistry Role of Early Growth Response-1 in the Development of Alcohol-Induced Steatosis
Current Molecular Pharmacology